Unexpectedly long persistence of anti‐SARS‐CoV‐2 spike monoclonal antibodies tixagevimab and cilgavimab in immunocompromised patients.

A study published in the journal Transplant Infectious Disease examined the persistence of anti-SARS-CoV-2 spike monoclonal antibodies (ViMAbs) tixagevimab and cilgavimab in immunocompromised patients. The study included 147 immunocompromised patients who had received at least one dose of Tix-Cil and had their antibody levels measured. The results showed that 92.6% of patients had antibody levels above 260 BAU/mL, with a median half-life of 259 days. The study suggests that ViMAbs may have a more heterogeneous and prolonged half-life in immunocompromised patients compared to previous reports. However, the use of Tix-Cil as a prophylactic or curative agent against the Omicron variant has been discontinued in France. [Extracted from the article]